Use of the 25 mm flanged esophageal z stent for Malignant dysphagia: A prospective multicenter trial

Richard A. Kozarek, Shirley Raltz, Norman Marcon, Paul Kortan, Gregory Haber, Charles Lightdale, Peter Stevens, Glen Lehman, Douglas Rex, Stanley Benjamin, David Fleischer, Roshan Bashir, Steven Fry, Irving Waxman, Jay Benson, John Polio

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: An initial multicenter study using a 21 mm flanged esophageal Z stent demonstrated excellent palliation but an 11% immediate complication rate at placement and a 27% migration rate at 1 month. This North American multicenter trial prospectively studied a 25 mm flanged Z stent to define its palliative ability and whether the increased diameter affected placement or migration problems. Methods: Fifty patients who had esophageal Z stents at seven university or regional referral hospitals were prospectively studied. Indications for prosthesis placement, previous therapy, patient demographics, incidence of concomitant tracheoesophageal fistula, and degree of dysphagia were defined, as were procedural and subsequent stent-related problems, survival times, the ability to occlude a tracheoesophageal fistula, and subsequent degree of dysphagia. Results: Twenty-four patients had infiltrating malignancy (16 exophytic and 10 extrinsic), 9 of whom had concomitant tracheoesophageal fistulas. Ten patients (20%) had misplaced stents requiring retrieval and replacement, 12 patients (24%) had subsequent stent-related problems including exsanguination (2), aspiration (3), tumor overgrowth (3), and postplacement migration (4) (8%). There was statistically significant improvement in prestent versus poststent dysphagia and two thirds of patients had complete occlusion of their tracheoesophageal fistula. Conclusions: Redesign of the esophageal Z stent has decreased the migration rate without increasing placement or subsequent erosion problems. Its efficacy appears comparable to the currently marketed Z stent for the palliation of malignant dysphagia and occlusion of tracheoesophageal fistula.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalGastrointestinal endoscopy
Volume46
Issue number2
DOIs
StatePublished - Jan 1 1997

Fingerprint

Deglutition Disorders
Multicenter Studies
Stents
Tracheoesophageal Fistula
Exsanguination
Prostheses and Implants
Neoplasms
Referral and Consultation
Demography
Survival
Incidence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

Kozarek, R. A., Raltz, S., Marcon, N., Kortan, P., Haber, G., Lightdale, C., ... Polio, J. (1997). Use of the 25 mm flanged esophageal z stent for Malignant dysphagia: A prospective multicenter trial. Gastrointestinal endoscopy, 46(2), 156-160. https://doi.org/10.1016/S0016-5107(97)70065-8

Use of the 25 mm flanged esophageal z stent for Malignant dysphagia : A prospective multicenter trial. / Kozarek, Richard A.; Raltz, Shirley; Marcon, Norman; Kortan, Paul; Haber, Gregory; Lightdale, Charles; Stevens, Peter; Lehman, Glen; Rex, Douglas; Benjamin, Stanley; Fleischer, David; Bashir, Roshan; Fry, Steven; Waxman, Irving; Benson, Jay; Polio, John.

In: Gastrointestinal endoscopy, Vol. 46, No. 2, 01.01.1997, p. 156-160.

Research output: Contribution to journalArticle

Kozarek, RA, Raltz, S, Marcon, N, Kortan, P, Haber, G, Lightdale, C, Stevens, P, Lehman, G, Rex, D, Benjamin, S, Fleischer, D, Bashir, R, Fry, S, Waxman, I, Benson, J & Polio, J 1997, 'Use of the 25 mm flanged esophageal z stent for Malignant dysphagia: A prospective multicenter trial', Gastrointestinal endoscopy, vol. 46, no. 2, pp. 156-160. https://doi.org/10.1016/S0016-5107(97)70065-8
Kozarek, Richard A. ; Raltz, Shirley ; Marcon, Norman ; Kortan, Paul ; Haber, Gregory ; Lightdale, Charles ; Stevens, Peter ; Lehman, Glen ; Rex, Douglas ; Benjamin, Stanley ; Fleischer, David ; Bashir, Roshan ; Fry, Steven ; Waxman, Irving ; Benson, Jay ; Polio, John. / Use of the 25 mm flanged esophageal z stent for Malignant dysphagia : A prospective multicenter trial. In: Gastrointestinal endoscopy. 1997 ; Vol. 46, No. 2. pp. 156-160.
@article{9b4dab78f7454bd7a09b032bae08d62a,
title = "Use of the 25 mm flanged esophageal z stent for Malignant dysphagia: A prospective multicenter trial",
abstract = "Background: An initial multicenter study using a 21 mm flanged esophageal Z stent demonstrated excellent palliation but an 11{\%} immediate complication rate at placement and a 27{\%} migration rate at 1 month. This North American multicenter trial prospectively studied a 25 mm flanged Z stent to define its palliative ability and whether the increased diameter affected placement or migration problems. Methods: Fifty patients who had esophageal Z stents at seven university or regional referral hospitals were prospectively studied. Indications for prosthesis placement, previous therapy, patient demographics, incidence of concomitant tracheoesophageal fistula, and degree of dysphagia were defined, as were procedural and subsequent stent-related problems, survival times, the ability to occlude a tracheoesophageal fistula, and subsequent degree of dysphagia. Results: Twenty-four patients had infiltrating malignancy (16 exophytic and 10 extrinsic), 9 of whom had concomitant tracheoesophageal fistulas. Ten patients (20{\%}) had misplaced stents requiring retrieval and replacement, 12 patients (24{\%}) had subsequent stent-related problems including exsanguination (2), aspiration (3), tumor overgrowth (3), and postplacement migration (4) (8{\%}). There was statistically significant improvement in prestent versus poststent dysphagia and two thirds of patients had complete occlusion of their tracheoesophageal fistula. Conclusions: Redesign of the esophageal Z stent has decreased the migration rate without increasing placement or subsequent erosion problems. Its efficacy appears comparable to the currently marketed Z stent for the palliation of malignant dysphagia and occlusion of tracheoesophageal fistula.",
author = "Kozarek, {Richard A.} and Shirley Raltz and Norman Marcon and Paul Kortan and Gregory Haber and Charles Lightdale and Peter Stevens and Glen Lehman and Douglas Rex and Stanley Benjamin and David Fleischer and Roshan Bashir and Steven Fry and Irving Waxman and Jay Benson and John Polio",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0016-5107(97)70065-8",
language = "English (US)",
volume = "46",
pages = "156--160",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Use of the 25 mm flanged esophageal z stent for Malignant dysphagia

T2 - A prospective multicenter trial

AU - Kozarek, Richard A.

AU - Raltz, Shirley

AU - Marcon, Norman

AU - Kortan, Paul

AU - Haber, Gregory

AU - Lightdale, Charles

AU - Stevens, Peter

AU - Lehman, Glen

AU - Rex, Douglas

AU - Benjamin, Stanley

AU - Fleischer, David

AU - Bashir, Roshan

AU - Fry, Steven

AU - Waxman, Irving

AU - Benson, Jay

AU - Polio, John

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Background: An initial multicenter study using a 21 mm flanged esophageal Z stent demonstrated excellent palliation but an 11% immediate complication rate at placement and a 27% migration rate at 1 month. This North American multicenter trial prospectively studied a 25 mm flanged Z stent to define its palliative ability and whether the increased diameter affected placement or migration problems. Methods: Fifty patients who had esophageal Z stents at seven university or regional referral hospitals were prospectively studied. Indications for prosthesis placement, previous therapy, patient demographics, incidence of concomitant tracheoesophageal fistula, and degree of dysphagia were defined, as were procedural and subsequent stent-related problems, survival times, the ability to occlude a tracheoesophageal fistula, and subsequent degree of dysphagia. Results: Twenty-four patients had infiltrating malignancy (16 exophytic and 10 extrinsic), 9 of whom had concomitant tracheoesophageal fistulas. Ten patients (20%) had misplaced stents requiring retrieval and replacement, 12 patients (24%) had subsequent stent-related problems including exsanguination (2), aspiration (3), tumor overgrowth (3), and postplacement migration (4) (8%). There was statistically significant improvement in prestent versus poststent dysphagia and two thirds of patients had complete occlusion of their tracheoesophageal fistula. Conclusions: Redesign of the esophageal Z stent has decreased the migration rate without increasing placement or subsequent erosion problems. Its efficacy appears comparable to the currently marketed Z stent for the palliation of malignant dysphagia and occlusion of tracheoesophageal fistula.

AB - Background: An initial multicenter study using a 21 mm flanged esophageal Z stent demonstrated excellent palliation but an 11% immediate complication rate at placement and a 27% migration rate at 1 month. This North American multicenter trial prospectively studied a 25 mm flanged Z stent to define its palliative ability and whether the increased diameter affected placement or migration problems. Methods: Fifty patients who had esophageal Z stents at seven university or regional referral hospitals were prospectively studied. Indications for prosthesis placement, previous therapy, patient demographics, incidence of concomitant tracheoesophageal fistula, and degree of dysphagia were defined, as were procedural and subsequent stent-related problems, survival times, the ability to occlude a tracheoesophageal fistula, and subsequent degree of dysphagia. Results: Twenty-four patients had infiltrating malignancy (16 exophytic and 10 extrinsic), 9 of whom had concomitant tracheoesophageal fistulas. Ten patients (20%) had misplaced stents requiring retrieval and replacement, 12 patients (24%) had subsequent stent-related problems including exsanguination (2), aspiration (3), tumor overgrowth (3), and postplacement migration (4) (8%). There was statistically significant improvement in prestent versus poststent dysphagia and two thirds of patients had complete occlusion of their tracheoesophageal fistula. Conclusions: Redesign of the esophageal Z stent has decreased the migration rate without increasing placement or subsequent erosion problems. Its efficacy appears comparable to the currently marketed Z stent for the palliation of malignant dysphagia and occlusion of tracheoesophageal fistula.

UR - http://www.scopus.com/inward/record.url?scp=0030865869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030865869&partnerID=8YFLogxK

U2 - 10.1016/S0016-5107(97)70065-8

DO - 10.1016/S0016-5107(97)70065-8

M3 - Article

C2 - 9283867

AN - SCOPUS:0030865869

VL - 46

SP - 156

EP - 160

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 2

ER -